Category Archives: Drug developments & targets

Ranbaxy-MMV-Antimalarial

Today Economic times reported that Ranbaxy received conditional approval for combination of its NCE molecule (Arterolane) and piperaquine phosphate. Drug Controller General of India ( DCGI) Surinder Singh said the marketing licence was subject to the condition that the Chinese plant … Continue reading

Posted in Daily interesting IP news, Drug developments & targets | Tagged , , , | 1 Comment

Breach of agreement-Onyx Vs Bayer-Sorafenib derivative

This is about breach of contract/collaborative agreement between onyx and bayer. [Press release] Recently Onyx and Bayer announced settlement agreement regarding the drug called “Regorafenib”(BAY73-4506). Regorafenib is structurally similar to sorafenib except a Fluoro substitution on sorafenib moiety. Sorafenib Regorafenib … Continue reading

Posted in Drug developments & targets | Tagged , , , | Leave a comment

CETP inhibitor Patent status

In addition to my previous post on CETP inhibitors, i here present patent status of some companies who involved in development of CETP inhibitor class of drugs. The method of using CETP inhibitors for treating atherosclerosis and cardiovascular conditions, were known … Continue reading

Posted in Drug developments & targets | Tagged , , | Leave a comment

Hepatitis C Cont…(3)

(Post 1) (Post 2) (Post 3) Medivir is also developing Hepatitis C drug (TMC435) with Tibotec Pharmaceuticals. Medivir announced positive interim Phase IIb data on efficacy of TMC 435. (Bloomberg) TMC435 is a once daily protease inhibitor jointly developed by … Continue reading

Posted in Drug developments & targets | Leave a comment

Study: CETP inhibitors

Cholesteryl ester transfer protein (CETP) inhibitors are new class of drugs to treat cardiovascular diseases, specifically CETP inhibitors improves high-density lipoproteins (HDL) level in blood. Research of CETP inhibitors might have started somewhere around 1990 to 1995 and PD 140195 … Continue reading

Posted in Drug developments & targets | Leave a comment

Hepatitis C cont…(2)

Some more updates from BMS and Abbott on newer Hepatitis C therapy (Post 1) (Post 2) Bristol Myers Squibb posts new data of investigational compounds (BMS-790052 and BMS-650032) and their combination with old therapies such as pegylated interferon and ribavirin. … Continue reading

Posted in Drug developments & targets | Leave a comment

Hepatitis C Cont…

In addition to my previous post on Hepatitis C drug development, BMS also updated new biotech development which is a novel Interferon in Development for the Treatment of Hepatitis C (PEG-Interferon Lambda). PEG-Interferon lambda is a novel and potential first-in-class interferon in development … Continue reading

Posted in Drug developments & targets | Leave a comment

Drug Targets: PDE10

PDE10 is a novel CNS drug target for schizophrenia treatments. Biotie, in collaboration with Pfizer, has demonstrated that inhibitors of PDE10 are active in experimental models relevant for schizophrenia. Data from these studies were recently presented at the American Chemical … Continue reading

Posted in Drug developments & targets | Leave a comment